Autologous and heterologous blood transfusion in head and neck cancer surgery

Melinda S. Moir, Ravi N. Samy, Matthew M. Hanasono, David J. Terris

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: To determine if the use of autologous blood ameliorates the increased risk for cancer recurrence that has been associated with perioperative blood transfusion. Design: Retrospective medical record review. Setting: Tertiary care hospital. Patients: One hundred sixty-five consecutive patients with stages II to IV squamous cell carcinoma of the head and neck treated surgically at a university hospital from January 1, 1989, through December 31, 1994. Main Outcome Measures: We evaluated the impact of perioperative autologous and heterologous blood transfusion and 10 other variables on recurrence. Univariate and multivariate analyses were used. Results: Heterologous blood recipients had a 59% recurrence rate, whereas those who had received autologous blood or no transfusion had recurrence rates of 33% and 35%, respectively. The following 4 variables had a statistically significant association with recurrence by multivariate analysis: previous treatment of current malignancy (P<.001); receipt of heterologous blood (P= .04); positive margin (P=.04); and nodal disease (P= .04). The receipt of heterologous blood was associated with a 40% increased risk for recurrence. Conclusion: Autologous blood products should be used during head and neck cancer surgery if possible when transfusion is necessary.

Original languageEnglish (US)
Pages (from-to)864-868
Number of pages5
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume125
Issue number8
DOIs
StatePublished - Aug 1999

Fingerprint

Autologous Blood Transfusions
Head and Neck Neoplasms
Recurrence
Multivariate Analysis
Tertiary Healthcare
Tertiary Care Centers
Blood Transfusion
Medical Records
Neoplasms
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Autologous and heterologous blood transfusion in head and neck cancer surgery. / Moir, Melinda S.; Samy, Ravi N.; Hanasono, Matthew M.; Terris, David J.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 125, No. 8, 08.1999, p. 864-868.

Research output: Contribution to journalArticle

Moir, Melinda S. ; Samy, Ravi N. ; Hanasono, Matthew M. ; Terris, David J. / Autologous and heterologous blood transfusion in head and neck cancer surgery. In: Archives of Otolaryngology - Head and Neck Surgery. 1999 ; Vol. 125, No. 8. pp. 864-868.
@article{c5c9c56b95b4478aa64b8e967a36907b,
title = "Autologous and heterologous blood transfusion in head and neck cancer surgery",
abstract = "Objective: To determine if the use of autologous blood ameliorates the increased risk for cancer recurrence that has been associated with perioperative blood transfusion. Design: Retrospective medical record review. Setting: Tertiary care hospital. Patients: One hundred sixty-five consecutive patients with stages II to IV squamous cell carcinoma of the head and neck treated surgically at a university hospital from January 1, 1989, through December 31, 1994. Main Outcome Measures: We evaluated the impact of perioperative autologous and heterologous blood transfusion and 10 other variables on recurrence. Univariate and multivariate analyses were used. Results: Heterologous blood recipients had a 59{\%} recurrence rate, whereas those who had received autologous blood or no transfusion had recurrence rates of 33{\%} and 35{\%}, respectively. The following 4 variables had a statistically significant association with recurrence by multivariate analysis: previous treatment of current malignancy (P<.001); receipt of heterologous blood (P= .04); positive margin (P=.04); and nodal disease (P= .04). The receipt of heterologous blood was associated with a 40{\%} increased risk for recurrence. Conclusion: Autologous blood products should be used during head and neck cancer surgery if possible when transfusion is necessary.",
author = "Moir, {Melinda S.} and Samy, {Ravi N.} and Hanasono, {Matthew M.} and Terris, {David J.}",
year = "1999",
month = "8",
doi = "10.1001/archotol.125.8.864",
language = "English (US)",
volume = "125",
pages = "864--868",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Autologous and heterologous blood transfusion in head and neck cancer surgery

AU - Moir, Melinda S.

AU - Samy, Ravi N.

AU - Hanasono, Matthew M.

AU - Terris, David J.

PY - 1999/8

Y1 - 1999/8

N2 - Objective: To determine if the use of autologous blood ameliorates the increased risk for cancer recurrence that has been associated with perioperative blood transfusion. Design: Retrospective medical record review. Setting: Tertiary care hospital. Patients: One hundred sixty-five consecutive patients with stages II to IV squamous cell carcinoma of the head and neck treated surgically at a university hospital from January 1, 1989, through December 31, 1994. Main Outcome Measures: We evaluated the impact of perioperative autologous and heterologous blood transfusion and 10 other variables on recurrence. Univariate and multivariate analyses were used. Results: Heterologous blood recipients had a 59% recurrence rate, whereas those who had received autologous blood or no transfusion had recurrence rates of 33% and 35%, respectively. The following 4 variables had a statistically significant association with recurrence by multivariate analysis: previous treatment of current malignancy (P<.001); receipt of heterologous blood (P= .04); positive margin (P=.04); and nodal disease (P= .04). The receipt of heterologous blood was associated with a 40% increased risk for recurrence. Conclusion: Autologous blood products should be used during head and neck cancer surgery if possible when transfusion is necessary.

AB - Objective: To determine if the use of autologous blood ameliorates the increased risk for cancer recurrence that has been associated with perioperative blood transfusion. Design: Retrospective medical record review. Setting: Tertiary care hospital. Patients: One hundred sixty-five consecutive patients with stages II to IV squamous cell carcinoma of the head and neck treated surgically at a university hospital from January 1, 1989, through December 31, 1994. Main Outcome Measures: We evaluated the impact of perioperative autologous and heterologous blood transfusion and 10 other variables on recurrence. Univariate and multivariate analyses were used. Results: Heterologous blood recipients had a 59% recurrence rate, whereas those who had received autologous blood or no transfusion had recurrence rates of 33% and 35%, respectively. The following 4 variables had a statistically significant association with recurrence by multivariate analysis: previous treatment of current malignancy (P<.001); receipt of heterologous blood (P= .04); positive margin (P=.04); and nodal disease (P= .04). The receipt of heterologous blood was associated with a 40% increased risk for recurrence. Conclusion: Autologous blood products should be used during head and neck cancer surgery if possible when transfusion is necessary.

UR - http://www.scopus.com/inward/record.url?scp=0032805438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032805438&partnerID=8YFLogxK

U2 - 10.1001/archotol.125.8.864

DO - 10.1001/archotol.125.8.864

M3 - Article

C2 - 10448732

AN - SCOPUS:0032805438

VL - 125

SP - 864

EP - 868

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 8

ER -